Edition:
United Kingdom

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

10.91USD
4:28pm BST
Change (% chg)

$-0.94 (-7.93%)
Prev Close
$11.85
Open
$11.80
Day's High
$11.80
Day's Low
$10.81
Volume
60,165
Avg. Vol
252,462
52-wk High
$16.38
52-wk Low
$2.62

Latest Key Developments (Source: Significant Developments)

Adverum Biotechnologies Q2 Loss Per Share $0.23
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.  Full Article

Adverum Biotechnologies Reports Q1 Loss Per Share $0.23
Wednesday, 8 May 2019 

May 8 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.EXPECTS QUARTER-END CASH POSITION TO FUND OPERATIONS INTO 2021..ADVERUM EXPECTS THIS QUARTER-END CASH POSITION TO FUND OPERATIONS INTO 2021.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $189.5 MILLION AS OF MARCH 31, 2019.  Full Article

Adverum Biotechnologies Provides Clinical Program Update On Advm-022 Gene Therapy For Wet AMD
Monday, 15 Apr 2019 

April 15 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES CLINICAL PROGRAM UPDATE ON ADVM-022 GENE THERAPY FOR WET AMD.ADVERUM BIOTECHNOLOGIES INC - CLINICAL HOLD UNTIL ADDITIONAL CMC INFORMATION IS REVIEWED BY FDA.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DMC REVIEW OF SAFETY DATA FROM FIRST COHORT OF SIX PATIENTS WITH NO SAES OR DLTS.ADVERUM BIOTECHNOLOGIES INC - ADVERUM PLANS TO PRESENT 24-WEEK DATA FROM FIRST COHORT OF PATIENTS AT SCIENTIFIC MEETING IN 2H19.ADVERUM BIOTECHNOLOGIES - INDEPENDENT DATA MONITORING COMMITTEE (DMC) DETERMINED THAT ENROLLMENT AND DOSING OF PATIENTS IN SECOND COHORT COULD PROCEED.ADVERUM - RECEIVED NOTIFICATION FROM FDA IN EARLY APRIL REQUESTING ADDITIONAL CMC INFORMATION AND REQUIREMENTS ON ADVM-022 MANUFACTURING PROCESS.ADVERUM BIOTECHNOLOGIES INC - FDA HAS PLACED COMPANY'S IND ON CLINICAL HOLD UNTIL AGENCY HAS REVIEWED ADVERUM'S RESPONSE.  Full Article

Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.25.Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.EXPECTS YEAR-END CASH POSITION TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURES INTO 2021.ON TRACK TO PROVIDE AN ENROLLMENT UPDATE IN FIRST HALF OF 2019 ON OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022.ADVERUM BIOTECHNOLOGIES - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $205.1 MILLION AS OF DEC 31, 2018 VERSUS $217.9 MILLION AS OF SEPT 30, 2018.QTRLY REVENUE, CONSISTING OF REVENUE FROM COLLABORATIVE RESEARCH, WAS $0.1 MILLION VERSUS $0.5 MILLION.  Full Article

Adverum Biotechnologies Provides 2019 Outlook
Monday, 7 Jan 2019 

Jan 6 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES 2019 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $217.9 MILLION AS OF SEPTEMBER 30, 2018.ADVERUM BIOTECHNOLOGIES INC - ADVERUM EXPECTS THIS QUARTER-END CASH POSITION TO FUND OPERATIONS AT LEAST THROUGH FIRST HALF OF 2020.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE AN UPDATE ON ENROLLMENT FROM OPTIC PHASE 1 CLINICAL TRIAL IN FIRST HALF OF 2019.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE INTERIM DATA ON THREE COHORTS FROM OPTIC PHASE 1 CLINICAL TRIAL BY Q1 OF 2020.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE AN UPDATE ON RARE DISEASE PROGRAM'S PRECLINICAL DEVELOPMENT PLAN IN FIRST HALF OF 2019.  Full Article

Adverum Biotechnologies Q2 Loss Per Share $0.30
Wednesday, 8 Aug 2018 

Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.30.Q2 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.REMAIN ON TRACK TO DELIVER ON GOALS IN SECOND HALF OF YEAR FOR THREE LEAD GENE THERAPIES.SECURED A NEW FACILITY TO OCCUPY IN SECOND HALF OF NEXT YEAR.  Full Article

Adverum Biotechnologies Provides 2018 Outlook
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017..ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019.ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA.  Full Article

Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Adverum Biotechnologies Inc ::HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING.  Full Article

Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY.ADVERUM BIOTECHNOLOGIES INC - ‍COMPANY EXPECTS TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018​.  Full Article

‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Adverum Biotechnologies Inc ::‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​.  Full Article